2024
Investigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis
Mutonga M, Shewarega A, Gross M, Kahl V, Madoff D. Investigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis. Clinical Imaging 2024, 115: 110283. PMID: 39278042, DOI: 10.1016/j.clinimag.2024.110283.Peer-Reviewed Original ResearchBeta-blockersTumor responseImaging timepointsTumor sizeEtiology of liver diseaseAssociated with high mortalityTransplant free survivalTransplant-free survivalTreatment of hepatocellular carcinomaFavorable clinical outcomesChild-Pugh scoreFirst-line treatmentBeta-blocker groupPredictors of survivalCox regression analysisTreatment of HCCStudent's t-testFree survivalTransarterial chemoembolizationChi-square testPost-TACETACE treatmentPugh scoreSurvival predictorsAdjunctive useLBA3 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
Llovet J, Finn R, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Li H, Kim J, Zhao H, Li C, Madoff D, Ghobrial R, El-Khoueiry A, Vogel A, Peng X, Mody K, Dubrovsky L, Kudo M. LBA3 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study. Annals Of Oncology 2024, 35: s1229. DOI: 10.1016/j.annonc.2024.08.2277.Peer-Reviewed Original Research
2022
LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)
El-Khoueiry A, Llovet J, Vogel A, Madoff D, Finn R, Ogasawara S, Ren Z, Mody K, Li J, Siegel A, Dubrovsky L, Kudo M. LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2022, 40: tps494-tps494. DOI: 10.1200/jco.2022.40.4_suppl.tps494.Peer-Reviewed Original ResearchBlinded independent central reviewIntermediate-stage hepatocellular carcinomaDisease control rateObjective response rateProgression-free survivalDuration of responseTransarterial chemoembolizationRECIST v1.1Hepatocellular carcinomaEnd pointCurative treatmentEastern Cooperative Oncology Group performance statusDual primary end pointsExploratory end pointsPrevious systemic treatmentPD-1 inhibitorsPortal vein thrombosisPrimary end pointSecondary end pointsSecond-line therapyPhase 3 studyHealth-related qualityIntermediate hepatocellular carcinomaAdvanced hepatocellular carcinomaLimited treatment options
2021
Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model
Doemel LA, Santana JG, Savic LJ, Gaupp FML, Borde T, Petukhova-Greenstein A, Kucukkaya AS, Schobert IT, Hamm CA, Gebauer B, Walsh JJ, Rexha I, Hyder F, Lin M, Madoff DC, Schlachter T, Chapiro J, Coman D. Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model. European Radiology 2021, 32: 2437-2447. PMID: 34718844, PMCID: PMC9359419, DOI: 10.1007/s00330-021-08337-3.Peer-Reviewed Original ResearchConceptsDrug-eluting embolicsImmune cell infiltrationAntigen-presenting cellsBicarbonate infusionConventional TACEDEE-TACETransarterial chemotherapyCell infiltrationImmune cellsPeritumoral infiltrationT lymphocytesIntratumoral immune cell infiltrationTumor modelRabbit VX2 liver tumor modelImmunological tumor microenvironmentVX2 liver tumor modelIntra-arterial therapyIntra-arterial treatmentRabbit VX2 tumor modelLiver tumor modelTumor-bearing rabbitsVX2 tumor modelMann-Whitney U testIntratumoral presenceTransarterial chemoembolizationThermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma
Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.Peer-Reviewed Original ResearchConceptsOverall survivalTransarterial chemoembolizationHepatocellular carcinomaThermal ablationTA groupEarly-stage hepatocellular carcinomaMedian overall survivalTherapy-naïve patientsKaplan-Meier analysisMaximum tumor diameterStage hepatocellular carcinomaLog-rank testDrug-eluting beadsSmall hepatocellular carcinomaTerms of TTPHIPAA-compliant IRBSignificant differencesLipiodol-TACELocoregional therapyBCLC stageComplication rateTreatment cohortsTumor diameterAFP levelsPatient group
2020
LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
Llovet J, El-Khoueiry A, Vogel A, Madoff D, Finn R, Ogasawara S, Ren Z, Mody K, Li J, Siegel A, Dubrovsky L, Kudo M. LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment. Annals Of Oncology 2020, 31: s702-s703. DOI: 10.1016/j.annonc.2020.08.1132.Peer-Reviewed Original ResearchP-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment
Ogasawara S, Llovet J, El-Khoueiry A, Vogel A, Madoff D, Finn R, Ren Z, Modi K, Li J, Siegel A, Dubrovsky L, Kudo M. P-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment. Annals Of Oncology 2020, 31: s124-s125. DOI: 10.1016/j.annonc.2020.04.189.Peer-Reviewed Original Research
2019
Balloon-Assisted Blood Pressure Reduction in the Downstream Vascular Compartment to Avoid Nontarget Embolization during Transarterial Chemoembolization from the Inferior Phrenic Artery
Stein SI, Madoff DC. Balloon-Assisted Blood Pressure Reduction in the Downstream Vascular Compartment to Avoid Nontarget Embolization during Transarterial Chemoembolization from the Inferior Phrenic Artery. Journal Of Vascular And Interventional Radiology 2019, 30: 1642-1644. PMID: 31101418, DOI: 10.1016/j.jvir.2018.12.010.Peer-Reviewed Original ResearchConceptsBlood pressure reductionInferior phrenic arteryPhrenic arteryTransarterial chemoembolizationNontarget embolizationVascular compartmentPressure reductionChemoembolizationEmbolizationArtery
2017
Balloon-Assisted Transarterial Chemoembolization: A Nascent Strategy for the Treatment of Hepatocellular Carcinoma
Kishore S, Cheng W, Smirniotopoulos J, Madoff D. Balloon-Assisted Transarterial Chemoembolization: A Nascent Strategy for the Treatment of Hepatocellular Carcinoma. Digestive Disease Interventions 2017, 01: 115-120. DOI: 10.1055/s-0037-1603961.Peer-Reviewed Original ResearchTransarterial chemoembolizationHepatocellular carcinomaLiver-confined hepatocellular carcinomaTreatment of HCCMajority of patientsBalloon catheter systemCancer-related mortalityLow-profile cathetersConventional transarterial chemoembolizationConventional TACECurative optionTransarterial therapiesLeading causeTherapeutic strategiesMicrocatheter technologyIntratumoral administrationChemotherapeutic agentsPatientsChemoembolizationCarcinomaTreatmentNascent strategyCatheterMajorityTherapy
2014
Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation
Kluger MD, Halazun KJ, Barroso RT, Fox AN, Olsen SK, Madoff DC, Siegel AB, Weintraub JL, Sussman J, Brown RS, Cherqui D, Emond JC. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transplantation 2014, 20: 536-543. PMID: 24493271, PMCID: PMC4095977, DOI: 10.1002/lt.23846.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, HepatocellularCase-Control StudiesChemoembolization, TherapeuticDisease-Free SurvivalEnd Stage Liver DiseaseFemaleHumansKaplan-Meier EstimateLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesTime FactorsTreatment OutcomeConceptsWait-list dropoutTAE patientsTACE patientsTransarterial embolizationTransarterial chemoembolizationHCC patientsEnd-stage liver disease (MELD) scoreSurvival rateRecurrence-free survival ratesMethods of embolizationRadiographic tumor sizeLiver Disease scoreOverall survival rateRecurrence-free survivalKaplan-Meier survivalBland transarterial embolizationCase-control studySignificant demographic differencesExplant tumorsPrimary endpointTreat basisTumor sizeHepatocellular carcinomaDisease scorePatients